Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radioimmunotherapy uses radiolabeled monoclonal antibodies to locate tumor cells
and deliver radioactive tumor-killing substances to them without harming normal cells.
Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy
use different ways to stop tumor cells from dividing so they stop growing or die. Combining
intrathecal radioimmunotherapy and radiation therapy with combination chemotherapy may kill
any tumor cells remaining after surgery.
PURPOSE: Phase II trial to study the effectiveness of combining intrathecal
radioimmunotherapy and radiation therapy with combination chemotherapy in treating patients
who have undergone surgery for medulloblastoma.